Posted on 10/31/2025 5:25:07 PM PDT by nickcarraway
The therapy, marketed as Zepbound and Mounjaro, took the crown from Merck at a striking pace
Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially been surpassed by Eli Lilly.
Lilly’s tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity, saw $10.1 billion in sales in the third quarter, the pharma giant said Thursday, bringing year-to-date sales of the product to $24.8 billion.
Merck, meanwhile, reported that Keytruda, a cancer immunotherapy, earned $8.1 billion in the third quarter, bringing year-to-date sales to $23.3 billion.
Tirzepatide took the crown at a striking pace — it was only approved for diabetes in 2022 and for obesity last year. In comparison, Keytruda became the best-selling drug nine years after it was first approved.
Analysts polled by Visible Alpha currently predict that for the full year, tirzepatide will bring in $32.2 billion, while Keytruda will bring in $31.8 billion.
The rapid passing of the torch underlines the immense demand for GLP-1-based drugs and the fierceness of the competition in the market. Even though Novo Nordisk was earlier to market with its highly effective drugs, Ozempic and Wegovy, Lilly is now widely seen as having surpassed Novo with a drug that can lead to even greater weight loss.
The intensity of competition in the obesity market was on full display Thursday, as Novo announced a takeover bid of biotech Metsera, which just a month ago said it would enter an acquisition deal with Pfizer.
When reporting earnings Thursday, Lilly said it brought in total revenue of $17.6 billion in the third quarter, greater than the $16.1 billion predicted by analysts.
The company also said it’s raising its guidance for full-year sales to the range of $63 to $63.5 billion, from a range of $60 to $62 billion and its guidance for adjusted earnings per share to a range of $23.00 to $23.70 from a range of $21.75 to $23.00.
Clarification: An earlier version of this story stated sales of Eli Lilly’s tirzepatide had surpassed sales of Merck’s Keytruda on a quarterly basis. It was the second consecutive time it had done so. Tirzepatide sales have now surpassed Keytruda on a year-to-date basis.
Wonder drugs in terms of what they can do.
But possible thyroid cancer risk, and Zepbound hasn’t been in the mass market very long.
These drugs act on the brain, gut, digestive system. They suppress certain molecular receptors.
What could go wrong, that is the question.
Well Lisa Marie found out what can go wrong.
Lisa Marie Presley died from a small bowel obstruction caused by complications of a prior bariatric surgery not from taking a weight loss pill.
I just started back on a double dose of victoza, which is the equivalent of Saxenda, which is said to be not quite as effective as these others, but it’s $36/month at our local community clinic, so I’m not complaining.
She'd never even taken it, she died from complications from surgery. Do you even bother to pretend to have the slightest idea of what you're talking about before you spout off?
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.